Motley Fool Australia

Why Botanix, Elixinol Global, Pro Medicus, & Tinybeans shares tumbled lower

Chalkboard Graph Up Dow

In afternoon trade the S&P/ASX 200 index is on course to give back yesterday’s gains. At the time of writing the benchmark index is down 0.25% to 6,655.5 points.

Four shares that have fallen more than most today are listed below. Here’s why they have tumbled lower:

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price has crashed 46% lower to 13 cents. Investors have been heading to the exits in their droves after the cannabis-focused medical dermatology company released topline data from its Phase 2 BTX 1503 study. That study was evaluating its safety and efficacy in patients with moderate to severe acne. Unfortunately, the topline data revealed that the primary endpoint of reducing inflammatory lesions did not achieve statistical significance.

The Elixinol Global Ltd (ASX: EXL) share price is down 10% to $1.90. The cannabis company’s shares have come under pressure today following the release of an update on its Japanese operations. According to the release, Elixinol Global has established that non-compliant hemp-derived cannabidiol (CBD) products were being sold by Elixinol Japan. This non-compliance relates to the strict requirements in Japan on sourcing CBD from only hemp stalk and seed.

The Pro Medicus Limited (ASX: PME) share price has fallen 6% to $28.25. The healthcare technology company’s shares have come under pressure today despite there being no news out of it. However, with its shares up significantly this year and trading on sky-high earnings multiples, I suspect that some investors have been taking a little profit off the table today.

The Tinybeans Group Ltd (ASX: TNY) share price has sunk 14.5% lower to $2.06. This morning the family-focused social media platform released its first quarter update. Although Tinybeans delivered strong revenue growth compared to the prior corresponding period, it fell quarter on quarter. At the end of the quarter, the company had Monthly Active Users of 1.28 million. This was up 50,000 on the previous quarter.

Forget what just happened. We think this stock could be Australia's next MONSTER IPO...

One little-known Australian IPO has doubled in value since January, and renowned Australian Moonshot stock picker Anirban Mahanti sees a potential millionaire-maker in waiting...

Because 'Doc' Mahanti believes this fast-growing company has all the hallmarks of genuine Moonshot potential, forget 'buy now pay later', this stock could be the next hot stock on the ASX.

Returns as of 6th October 2020

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia has recommended Pro Medicus Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Related Articles...